Heterocyclic amide derivative and pharmaceutical product containing same

1. A compound represented by formula (I):

wherein

Ar 1 is a C 6-10 aryl group having substituent(s), a C 1-9 heteroaryl group having substituent(s), or a C 3-7 cycloalkyl group having substituent(s);

Ar 2 is a C 6-10 aryl group having substituent(s), a C 1-9 heteroaryl group having substituent(s), or a C 3-7 cycloalkyl group having substituent(s);

partial structure (1)

is a divalent group of a 5-membered heteroaromatic ring (ring A) containing 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, a sulfur atom and an oxygen atom, and optionally having 1-3 substituents;

W is C(R b )(R c ) or a single bond;

X is C(R d )(R e ), a sulfur atom, or a single bond;

Y is C(R f )(R g ) or a single bond;

when any two of W, X and Y are single bonds, the remaining one is not a single bond;

R b , R c , R d , R e , R f , and R g are the same or different and each is a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a halogeno-C 1-6 alkyl group, a C 1-6 alkoxy group, a hydroxyl group, a halogeno-C 1-6 alkoxy group, an amino group, an amino group mono- or di-substituted by a C 1-6 alkyl group, or a halogeno group; or

respective R b , R c , R d , and R e on the adjacent carbon atoms are optionally joined to form a ring; and respective R d , R e , R f , and R g on the adjacent carbon atoms are optionally joined to form a double bond and/or a ring;

R 1 is a hydrogen atom, a hydroxyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a halogeno-C 1-6 alkyl group, a cyclic C 3-6 alkyl group, or a C 1-6 alkyl group substituted by a cyclic C 3-6 alkyl group;

R 2 and R 3 are the same or different and each is a hydrogen atom, a halogen atom, a hydroxyl group, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a cyclic C 3-6 alkyl group (optionally containing a hetero atom in the ring), a C 6-10 aryl group optionally having substituent(s), a C 1-9 heteroaryl group optionally having substituent(s), a C 1-6 alkyl group substituted by a hydroxyl group, a C 1-6 alkyl group substituted by a C 6-10 aryl group optionally having substituent(s), or a C 1-6 alkyl group substituted by a C 1-9 heteroaryl group optionally having substituent(s); and

R 4 is a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, or a C 2-6 alkynyl group,

provided that:

(1) when R 2 or R 3 is a methyl group, Ar 2 is not a phenyl group substituted by a fluorine atom;

(2) when Ar 1 is a phenyl group substituted by a fluorine atom, ring A in partial structure (1) is not furan or thiophene;

(3) when Ar 1 is a phenyl group substituted by a methoxy group, ring A in partial structure (1) is not thiophene; and

(4) when Ar 1 is a phenyl group substituted by a methyl group, ring A in partial structure (1) is not oxadiazole, and Ar 2 is not a methoxyphenyl group,

or a pharmaceutically acceptable salt thereof.

2. The compound or pharmaceutically acceptable salt according to claim 1 , wherein

partial structure (2)

is none of the following structures:

3. The compound or pharmaceutically acceptable salt according to claim 1 , wherein

Ar 1 is a C 6-10 aryl group having one or more substituents selected from the group consisting of a halogeno group, a halogeno-C 1-6 alkyl group, a halogeno-C 1-6 alkoxy group, and a C 1-6 alkyl group; or Ar 1 is a C 1-9 heteroaryl group having one or more substituents selected from the group consisting of a halogeno group, a halogeno-C 1-6 alkyl group, a halogeno-C 1-6 alkoxy group, and a C 1-6 alkyl group.

4. The compound or pharmaceutically acceptable salt according to claim 1 , wherein

Ar 2 is a phenyl group having one or more substituents selected from the group consisting of a halogeno-C 1-6 alkyl group, a halogeno-C 1-6 alkoxy group, a C 1-6 alkyl group, and a halogeno group.

5. The compound or pharmaceutically acceptable salt according to claim 1 , wherein

R 1 is a hydrogen atom.

6. The compound or pharmaceutically acceptable salt according to claim 1 , wherein

Ar 1 is a C 6-10 aryl group having one or more substituents selected from the group consisting of a halogeno group, a halogeno-C 1-6 alkyl group, a halogeno-C 1-6 alkoxy group, and a C 1-6 alkyl group; or Ar 1 is a C 1-9 heteroaryl group having one or more substituents selected from the group consisting of a halogeno group, a halogeno-C 1-6 alkyl group, a halogeno-C 1-6 alkoxy group, and a C 1-6 alkyl group;

R 1 is a hydrogen atom; and

partial structure (1) is

wherein in the above-mentioned structures, R a is a hydrogen atom or a substituent, and each R a may be the same or different.

7. The compound or pharmaceutically acceptable salt according to claim 1 , wherein

Ar 2 is a phenyl group having one or more substituents selected from the group consisting of a halogeno-C 1-6 alkyl group, a halogeno-C 1-6 alkoxy group, a C 1-6 alkyl group, and a halogeno group,

R 1 is a hydrogen atom; and

in the formula (I), partial structure (1) is

wherein in the above-mentioned structures, R a is a hydrogen atom or a substituent, and each R a may be the same or different.

8. The compound or pharmaceutically acceptable salt according to claim 1 , wherein

Ar 1 is a C 6-10 aryl group having one or more substituents selected from the group consisting of a halogeno group, a halogeno-C 1-6 alkyl group, a halogeno-C 1-6 alkoxy group, and a C 1-6 alkyl group; or Ar 1 is a C 1-9 heteroaryl group having one or more substituents selected from the group consisting of a halogeno group, a halogeno-C 1-6 alkyl group, a halogeno-C 1-6 alkoxy group, and a C 1-6 alkyl group;

Ar 2 is a phenyl group having one or more substituents selected from the group consisting of a halogeno-C 1-6 alkyl group, a halogeno-C 1-6 alkoxy group, a C 1-6 alkyl group, and a halogeno group;

R 1 is a hydrogen atom; and

in the formula (I), partial structure (1) is

wherein in the above-mentioned structures, R a is a hydrogen atom or a substituent, and each R a may be the same or different.

9. The compound or pharmaceutically acceptable salt according to claim 1 , wherein

partial structure (1) is

wherein in the above-mentioned structures, R a is a hydrogen atom or a substituent, and each R a may be the same or different.

10. A compound selected from the group consisting of:

(2S)-1-(5-chlorothiophene-2-sulfonyl)-N-({4-[4-(trifluoromethyl)phenyl]thiazol-2-yl}methyl)pyrrolidine-2-carboxamide;

(2S)-1-(5-chlorothiophene-2-sulfonyl)-N-({4-[4-(trifluoromethoxy)phenyl]thiazol-2-yl}methyl)pyrrolidine-2-carboxamide;

(2S)-1-(5-chlorothiophene-2-sulfonyl)-N-({4-[3-fluoro-4-(trifluoromethoxy)phenyl]thiazol-2-yl}methyl)pyrrolidine-2-carboxamide;

(2S)-1-(5-chlorothiophene-2-sulfonyl)-N-({5-methyl-4-[4-(trifluoromethyl)phenyl]thiazol-2-yl}methyl)pyrrolidine-2-carboxamide;

(2S)-1-(5-chlorothiophene-2-sulfonyl)-N-({4-[4-(trifluoromethoxy)phenyl]oxazol-2-yl}methyl)pyrrolidine-2-carboxamide;

(2S)-1-(5-chlorothiophene-2-sulfonyl)-N-({2-[4-(trifluoromethyl)phenyl]thiazol-4-yl}methyl)pyrrolidine-2-carboxamide;

(2S)-1-(5-chlorothiophene-2-sulfonyl)-N-({4-[4-(trifluoromethyl)phenyl]thiazol-2-yl}methyl)-3,4-didehydropyrrolidine-2-carboxamide;

(2S)-1-(5-chlorothiophene-2-sulfonyl)-N-({4-[4-(trifluoromethoxy)phenyl]thiazol-2-yl}methyl)-3,4-didehydropyrrolidine-2-carboxamide;

(2S)-1-(5-chlorothiophene-2-sulfonyl)-N-({4-[3-fluoro-4-(trifluoromethoxy)phenyl]thiazol-2-yl}methyl)-3,4-didehydropyrrolidine-2-carboxamide;

(2S)-1-(5-chlorothiophene-2-sulfonyl)-N-({5-methyl-4-[4-(trifluoromethyl)phenyl]thiazol-2-yl}methyl)-3,4-didehydropyrrolidine-2-carboxamide;

(2S)-1-(5-chlorothiophene-2-sulfonyl)-N-({2-[4-(trifluoromethyl)phenyl]thiazol-4-yl}methyl)-3,4-didehydropyrrolidine-2-carboxamide;

(2S)-1-(5-bromothiophene-2-sulfonyl)-N-({4-[4-(trifluoromethyl)phenyl]thiazol-2-yl}methyl)pyrrolidine-2-carboxamide;

(2S)-1-(5-chlorothiophene-2-sulfonyl)-N-({5-[4-(trifluoromethoxy)phenyl]-2-thienyl})methyl)pyrrolidine-2-carboxamide;

(2S)-1-(5-chlorothiophene-2-sulfonyl)-N-({5-methyl-2-[4-(trifluoromethyl)phenyl]thiazol-4-yl}methyl)pyrrolidine-2-carboxamide;

(2S)-1-(3-fluorophenyl)sulfonyl-N-({4-[4-(trifluoromethyl)phenyl]thiazol-2-yl}methyl)pyrrolidine-2-carboxamide;

(2S)-1-(3,4-difluorophenyl)sulfonyl-N-({4-[4-(trifluoromethyl)phenyl]thiazol-2-yl}methyl)pyrrolidine-2-carboxamide; and

(2S)-1-(3,5-difluorophenyl)sulfonyl-N-({4-[4-(trifluoromethyl)phenyl]thiazol-2-yl})methyl)pyrrolidine-2-carboxamide,

or a pharmaceutically acceptable salt of said compound.

11. A medicament, comprising a compound or pharmaceutically acceptable salt according to claim 1 and a pharmaceutically acceptable carrier or excipient.